

Supplemental Table S3. Clinical Characteristics by Last Follow-up Status

Characteristic	BCR (n=113)	BCD or SD (n=64)	PD or dead due to MTC (n=49)	P value
Year				<0.001
1980–2009	50 (44)	39 (61)	31 (63)	
2010–2020	63 (56)	25 (39)	18 (37)	
Female sex	82 (73)	41 (64)	21 (43)	0.001
Age, yr	49.0±15.6	43.0±15.1	52.7±14.0	0.003
Hereditary	53 (24)	27 (23)	26 (25)	0.719
Operation				
Surgical extent, less than TT/TT	10 (9)/103 (91)	3 (3)/61 (95)	4 (8)/45 (92)	0.606
Lymph node extent ^a , CND/LND/none	64 (57)/22 (19)/24 (21)	21 (33)/27 (42)/8 (13)	3 (6)/33 (67)/7 (14)	<0.001
Pathology				
Tumor size in greatest length, cm	1.6±1.2	2.2±1.6	3.7±2.4	<0.001
ETE, none/microscopic/gross	93 (88)/11 (10)/2 (2)	30 (60)/15 (30)/5 (10)	6 (18)/15 (45)/12 (36)	<0.001
Lymph node metastasis ^b , none/CN/LN	54 (48)/19 (17)/11 (10)	7 (11)/16 (25)/23 (36)	3 (6)/7 (14)/22 (45)	<0.001
Resection margin positive status	3 (3)	4 (8)	5 (14)	0.011
Combined thyroid pathology, PTC/FTC	20 (18)/2 (2)	4 (12)/0	2 (9)/0	0.008
Initial distant metastasis	0	2 (3)	6 (12)	<0.001
Postoperative neck radiotherapy	11 (10)	9 (14)	21 (43)	<0.001
Recurrence outcomes				
Follow-up period, mo	102.0 (57.0–149.0)	60.0 (30.75–107.3)	27.0 (9.0–68.0)	<0.001
Recurrence/persistence	8 (7)/0	45 (70)/2 (4)	39 (80)/6 (22)	<0.001
Cumulative recurrence rate at 5/10/20/30 years, %	4.0/8.2/14.3/14.3	43.8/33.6/85.4/92.7	68.6/90.3/100.0/100.0	0.240
Sites of recurrence ^c				
LN/mediastinum/distant organs	8 (100)/0/2 (25)	40 (89)/6 (13)/15 (33)	35 (90)/19 (49)/29 (74)	<0.001
Single/multiple	6 (75)/2 (25)	31 (69)/14 (31)	6 (15)/33 (85)	<0.001
Survival outcomes				
Follow-up period, mo	115.0 (67.0–153.0)	136.5 (63.3–225.0)	104.0 (43.0–142.0)	<0.001
Mortality, MTC-specific/all causes	0/4 (4)	0/5 (8)	32 (65)/34 (69)	<0.001/<0.001

Values are expressed as number (%), mean±standard deviation, or median (interquartile range).

BCR, biochemical remission; BCD, biochemical disease; SD, stable disease; PD, progressive disease; MTC, medullary thyroid carcinoma; TT, total thyroidectomy; CND, central node dissection; LND, lateral node dissection; ETE, extrathyroidal extension; CN, central node; LN, lateral node; PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma.

^aAvailable information for 110 patients in the BCR group, 56 patients in the BCD or SD group, and 43 patients in the PD or dead due to MTC group; ^bAvailable information for 84 patients in the BCR group, 46 patients in the BCD or SD group, and 32 patients in the PD or dead due to MTC group; ^cPercentages are relative to only eight recurrent patients in the BCR group, 45 patients in the BCD or SD group, and 39 patients in the PD or dead due to MTC group.